R_4'' is −H, −OH, −F, −Cl, −Br, −I, $-NH_2$, $-NO_2$, −CN, −SH, $-S(O)_2OH$, or $-S(O)_2NH_2$, or $alkyl_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, $amido_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $-C(O)-alkoxy_{(C\leq 8)}$, $-C(O)-alkylamino_{(C\leq 8)}$, $-C(O)-dialkyl\text{-}amino_{(C\leq 8)}$, $alkylsulfonyl_{(C\leq 8)}$, $arylsulfonyl_{(C\leq 8)}$, $alkoxysulfonyl_{(C\leq 8)}$, or a substituted version of any of these groups; or

$$-X_2-(CH_2)_p-R_4'''$$;

wherein:

X_2 is $arenediyl_{(C\leq 12)}$, substituted $arenediyl_{(C\leq 12)}$, $heterocycloalkanediyl_{(C\leq 12)}$, substituted $heterocycloalkanediyl_{(C\leq 12)}$, $heteroarenediyl_{(C\leq 12)}$, or substituted $heteroarenediyl_{(C\leq 12)}$;

p is 0, 1, 2, 3, or 4; and

R_4''' is $alkyl_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, $amido_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $-C(O)-alkoxy_{(C\leq 8)}$, $-C(O)-alkylamino_{(C\leq 8)}$, $-C(O)-dialkyl\text{-}amino_{(C\leq 8)}$, $alkylsulfonyl_{(C\leq 8)}$, $arylsulfonyl_{(C\leq 8)}$, $alkoxysulfonyl_{(C\leq 8)}$, or a substituted version of any of these groups; and

R_5 is amino, hydroxy, isopropoxy, $-OS(O)_2C_6H_4CH_3$, $alkyl_{(C\leq 12)}$, $cycloalkyl_{(C\leq 12)}$, $cycloalkoxy_{(C\leq 12)}$, $aryl_{(C\leq 12)}$, $aralkyl_{(C\leq 12)}$, $heteroaryl_{(C\leq 12)}$, $heteroaralkyl_{(C\leq 12)}$, $heterocycloalkyl_{(C\leq 12)}$, $acyl_{(C\leq 12)}$, $acyloxy_{(C\leq 12)}$, $alkylamino_{(C\leq 12)}$, $dialkylamino_{(C\leq 12)}$, $alkylsulfonylamino_{(C\leq 12)}$, or a substituted version of any of the last thirteen groups, or

$$-OY_1-A_1$$;

wherein:

Y_1 is $alkanediyl_{(C\leq 8)}$ or substituted $alkanediyl_{(C\leq 8)}$; and

A_1 is $cycloalkyl_{(C\leq 8)}$ or substituted $cycloalkyl_{(C\leq 8)}$; or

$$-Y_2-C(O)NR_c-A_2$$;

wherein:

Y_2 is $arenediyl_{(C\leq 8)}$ or substituted $arenediyl_{(C\leq 8)}$;

R_c is hydrogen, $alkyl_{(C\leq 6)}$, or substituted $alkyl_{(C\leq 6)}$; and

A_2 is $aralkyl_{(C\leq 12)}$ or substituted $aralkyl_{(C\leq 12)}$; or

$$-A_3R_d$$;

wherein:

A_3 is −O− or $-NR_e-$, wherein

R_e is hydrogen, $alkyl_{(C\leq 6)}$, or substituted $alkyl_{(C\leq 6)}$; and

R_d is $acyl_{(C\leq 12)}$, or substituted $acyl_{(C\leq 12)}$;

provided that when carbon atoms 4 and 5 are joined by a double bond, then R_2' and the hydrogen atom at carbon atom 5 are absent;

wherein the term "substituted" when used to modify any group means that one or more hydrogen atom on that group has been independently replaced by −OH, −F, −Cl, −Br, −I, $-NH_2$, $-NO_2$, $-CO_2H$, −C(O)H, $-CO_2CH_3$, −CN, −SH, $-OCH_3$, $-OCH_2CH_3$, $-C(O)CH_3$, $-NHCH_3$, $-NHCH_2CH_3$, $-N(CH_3)_2$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)N(CH_3)_2$, $-OC(O)CH_3$, $-NHC(O)CH_3$, $-S(O)_2CH_3$, $-S(O)_2OH$, or $-S(O)_2NH_2$;


wherein the term “aryl” does not preclude the presence of one or more alkyl group attached to any aromatic ring;


wherein the term “heteroaryl” does not preclude the presence of one or more alkyl, cycloalkyl, heterocycloalkyl, aryl, and/or aralkyl groups attached to one or more ring atoms; and


wherein the term “heterocycloalkyl” does not preclude the presence of one or more alkyl groups attached to one or more ring atoms;


or a pharmaceutically acceptable salt thereof.


In yet another aspect, the present disclosure refers to a compound of the formula:



,


,


,



, or


;

or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS:

1. A compound of the formula:



(I)

wherein:

the bond between carbon atoms 1 and 2 is a single bond, an epoxidized double bond, or a double bond;

the bond between carbon atoms 4 and 5 is a single bond or a double bond;

a is 0, 1, or 2;

R_1 is cyano, heteroaryl$_{(C\leq 8)}$, substituted heteroaryl$_{(C\leq 8)}$, $-CF_3$, or $-C(O)R_a$; wherein:


R_a is hydroxy, amino, or alkoxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, alkylsulfonylamino$_{(C\leq 8)}$, or a substituted version of any of these groups;

R_2 is hydrogen or alkyl$_{(C\leq 12)}$, cycloalkyl$_{(C\leq 12)}$, alkenyl$_{(C\leq 12)}$, alkynyl$_{(C\leq 12)}$, aryl$_{(C\leq 12)}$, aralkyl$_{(C\leq 12)}$, heteroaryl$_{(C\leq 12)}$, heteroaralkyl$_{(C\leq 12)}$, acyl$_{(C\leq 12)}$, or a substituted version of any of these groups, or −alkanediyl$_{(C\leq 8)}$−cycloalkyl$_{(C\leq 12)}$ or a substituted version of this group;

R_2' is absent, hydrogen, or alkyl$_{(C\leq 12)}$, cycloalkyl$_{(C\leq 12)}$, alkenyl$_{(C\leq 12)}$, alkynyl$_{(C\leq 12)}$, aryl$_{(C\leq 12)}$, aralkyl$_{(C\leq 12)}$, heteroaryl$_{(C\leq 12)}$, heteroaralkyl$_{(C\leq 12)}$, acyl$_{(C\leq 12)}$, or a substituted version of these groups; provided that when the bond between carbon atoms 4 and 5 is a double bond then R_2' is absent;

R_3 is alkyl$_{(C\leq 12)}$, alkenyl$_{(C\leq 12)}$, aryl$_{(C\leq 12)}$, aralkyl$_{(C\leq 12)}$, or a substituted version of any of these groups;

R_4 is cycloalkyl$_{(C\leq 18)}$, substituted cycloalkyl$_{(C\leq 18)}$, aryl$_{(C\leq 18)}$, substituted aryl$_{(C\leq 18)}$, heteroaryl$_{(C\leq 18)}$, substituted heteroaryl$_{(C\leq 18)}$, heterocycloalkyl$_{(C\leq 18)}$, substituted heterocycloalkyl$_{(C\leq 18)}$, or



;

wherein:

n is 0, 1, 2, 3, or 4; and

R_4'' is −H, −OH, −F, −Cl, −Br, −I, $-NH_2$, $-NO_2$, −CN, −SH, $-S(O)_2OH$, or $-S(O)_2NH_2$, or $alkyl_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, $amido_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $-C(O)-alkoxy_{(C\leq 8)}$, $-C(O)-alkylamino_{(C\leq 8)}$, $-C(O)-dialkyl\text{-}amino_{(C\leq 8)}$, $alkylsulfonyl_{(C\leq 8)}$, $arylsulfonyl_{(C\leq 8)}$, $alkoxysulfonyl_{(C\leq 8)}$, or a substituted version of any of these groups; or

$$-X_2-(CH_2)_p-R_4'''$$;

wherein:

X_2 is $arenediyl_{(C\leq 12)}$, substituted $arenediyl_{(C\leq 12)}$, $heterocycloalkanediyl_{(C\leq 12)}$, substituted $heterocycloalkanediyl_{(C\leq 12)}$, $heteroarenediyl_{(C\leq 12)}$, or substituted $heteroarenediyl_{(C\leq 12)}$;

p is 0, 1, 2, 3, or 4; and

R_4''' is $alkyl_{(C\leq 8)}$, $cycloalkyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $acyl_{(C\leq 8)}$, $amido_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $-C(O)-alkoxy_{(C\leq 8)}$, $-C(O)-alkylamino_{(C\leq 8)}$, $-C(O)-dialkyl\text{-}amino_{(C\leq 8)}$, $alkylsulfonyl_{(C\leq 8)}$, $arylsulfonyl_{(C\leq 8)}$, $alkoxysulfonyl_{(C\leq 8)}$, or a substituted version of any of these groups; and

R_5 is amino, hydroxy, isopropoxy, $-OS(O)_2C_6H_4CH_3$, $alkyl_{(C\leq 12)}$, $cycloalkyl_{(C\leq 12)}$, $cycloalkoxy_{(C\leq 12)}$, $aryl_{(C\leq 12)}$, $aralkyl_{(C\leq 12)}$, $heteroaryl_{(C\leq 12)}$, $heteroaralkyl_{(C\leq 12)}$, $heterocycloalkyl_{(C\leq 12)}$, $acyl_{(C\leq 12)}$, $acyloxy_{(C\leq 12)}$, $alkylamino_{(C\leq 12)}$, $dialkylamino_{(C\leq 12)}$, $alkylsulfonylamino_{(C\leq 12)}$, or a substituted version of any of the last thirteen groups, or

$$-OY_1-A_1$$;

wherein:

Y_1 is $alkanediyl_{(C\leq 8)}$ or substituted $alkanediyl_{(C\leq 8)}$; and

A_1 is $cycloalkyl_{(C\leq 8)}$ or substituted $cycloalkyl_{(C\leq 8)}$; or

$$-Y_2-C(O)NR_c-A_2$$;

wherein:

Y_2 is $arenediyl_{(C\leq 8)}$ or substituted $arenediyl_{(C\leq 8)}$;

R_c is hydrogen, $alkyl_{(C\leq 6)}$, or substituted $alkyl_{(C\leq 6)}$; and

A_2 is $aralkyl_{(C\leq 12)}$ or substituted $aralkyl_{(C\leq 12)}$; or

$-A_3R_d$;

wherein:

A_3 is $-O-$ or $-NR_e-$, wherein

R_e is hydrogen, $alkyl_{(C\leq 6)}$, or substituted $alkyl_{(C\leq 6)}$; and

R_d is $acyl_{(C\leq 12)}$, or substituted $acyl_{(C\leq 12)}$;

provided that when carbon atoms 4 and 5 are joined by a double bond, then R_2' and the hydrogen atom at carbon atom 5 are absent;

wherein the term "substituted" when used to modify any group means that one or more hydrogen atom on that group has been independently replaced by $-OH$, $-F$, $-Cl$, $-Br$, $-I$, $-NH_2$, $-NO_2$, $-CO_2H$, $-C(O)H$, $-CO_2CH_3$, $-CN$, $-SH$, $-OCH_3$, $-OCH_2CH_3$, $-C(O)CH_3$, $-NHCH_3$, $-NHCH_2CH_3$, $-N(CH_3)_2$, $-C(O)NH_2$, $-C(O)NHCH_3$, $-C(O)N(CH_3)_2$, $-OC(O)CH_3$, $-NHC(O)CH_3$, $-S(O)_2CH_3$, $-S(O)_2OH$, or $-S(O)_2NH_2$;


wherein the term "aryl" does not preclude the presence of one or more alkyl group attached to any aromatic ring;

wherein the term "heteroaryl" does not preclude the presence of one or more alkyl, cycloalkyl, heterocycloalkyl, aryl, and/or aralkyl groups attached to one or more ring atoms; and

wherein the term "heterocycloalkyl" does not preclude the presence of one or more alkyl groups attached to one or more ring atoms;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 further defined as:



(VII)

wherein:

R_2 is hydrogen, $alkyl_{(C\leq 12)}$, or substituted $alkyl_{(C\leq 12)}$;

R_4 is $heteroaryl_{(C\leq 18)}$ or substituted $heteroaryl_{(C\leq 18)}$; and

R_5 is $aryl_{(C\leq 12)}$ or substituted $aryl_{(C\leq 12)}$;

or a pharmaceutically acceptable salt thereof.

3. The compound according claim 1, wherein R_1 is cyano.

4. The compound according to any one of claims 1-3, wherein R_2 is $alkyl_{(C\leq12)}$ or substituted $alkyl_{(C\leq12)}$.

5. The compound according to any one of claims 1-4, wherein R_2' is hydrogen, $alkyl_{(C\leq12)}$, or substituted $alkyl_{(C\leq12)}$, or R_3 is $alkyl_{(C\leq12)}$ or substituted $alkyl_{(C\leq12)}$.

6. The compound according to any one of claims 1-5, wherein R_4 is $heteroaryl_{(C\leq18)}$ or substituted $heteroaryl_{(C\leq18)}$.

7. The compound of claim 6, wherein R_4 is a $heteroaryl_{(C\leq12)}$ or a substituted $heteroaryl_{(C\leq12)}$ group wherein at least one of the heteroatoms in the aromatic ring is a nitrogen atom.

8. The compound of claim 6, wherein R_4 is $heteroaryl_{(C\leq18)}$.

9. The compound of claim 6, wherein R_4 is 3-pyridinyl, 4-pyridinyl, 4-(2-cylopropyl)-pyridinyl, 5-(2-cylopropyl)-pyridinyl, 4-(2-morpholino)-pyridinyl, 4-(2-phenyl)-pyridinyl, 3-(5-methyl)-pyridinyl, 3-(6-methyl)-pyridinyl, 4-(2-methyl)-pyridinyl, 4-(3-methyl)-pyridinyl, 3-pyrazolo[1,5-*a*]pyridinyl, 3-(*N*-methyl)-pyrrolo[2,3-*b*]pyridinyl, 5-isoquinolinyl, 2-isoquinolinyl, 1-isoquinolinyl, 4-(2-phenyl)-pyridinyl, 5-(2-phenyl)-pyridinyl, 4-(3,5-dimethyl)-isoxazolyl, 3-(4-methyl)-pyridinyl, 4-(6-methyl)-pyrimidinyl, 6-(4-methyl)-pyrimidinyl, 4-pyridazinyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 8-quinolinyl, 4-isoquinolinyl, 3-(8-methyl)-quinolinyl, 3-(1-methyl)-quinolinyl, 4-(2-methyl)-quinolinyl, 4-(2-isopropyl)-quinolinyl, 4-(6-methyl)-quinolinyl, 4-(7-methyl)-quinolinyl, 4-(8-methyl)-quinolinyl, 2-(*N*-methyl)-indolyl, 5-(2,4-dimethyl)-thiazolyl, or 5-(3-methyl)-oxadizolyl.

10. The compound of claim 6, wherein R_4 is substituted $heteroaryl_{(C\leq18)}$.

11. The compound of claim 10, wherein R_4 is 4-(2-trifluoromethyl)-pyridinyl, 4-(3-fluoro)-pyridinyl, 4-(2-methoxy)-pyridinyl, 4-(2-hydroxymethyl)-pyridinyl, 4-(2-acetylamino)-pyridinyl, 4-(2-fluoromethyl)-pyridinyl, 4-(2-acetamidylethyl)-pyridinyl, 4-(2-fluoromethyl)-quinolinyl, 4-(2-acetoxymethyl)-quinolinyl, 4-(2-formyl)-quinolinyl, 4-(6-fluoro)-quinolinyl, 4-(7-fluoro)-quinolinyl, 4-(8-fluoro)-quinolinyl, 4-(6,8-difluoro)-quinolinyl, 4-(6-fluoro-2-methyl)-quinolinyl, or 4-(8-fluoro-2-methyl)-quinolinyl.

12. The compound according to any one of claims 1-5, wherein R_4 is $aryl_{(C\leq12)}$ or substituted $aryl_{(C\leq12)}$.

13. The compound according to any one of claims 1-12, wherein R_5 is $aryl_{(C\leq12)}$ or substituted $aryl_{(C\leq12)}$.

14. The compound of claim 13, wherein R_5 is $aryl_{(C\leq12)}$.










15. The compound of claim 13, wherein R_5 is phenyl, 4-methylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 1,3-biphenyl, or 1,4-biphenyl.
















16. The compound of claim 13, wherein R_5 is a substituted $aryl_{(C\leq12)}$ wherein one or more hydrogen atoms of the $aryl_{(C\leq12)}$ has been independently replaced by −F.
















17. The compound of claim 13, wherein R_5 is substituted $aryl_{(C\leq12)}$.














18. The compound of claim 17, wherein R_5 is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 4-hydroxymethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 4-chlorophenyl, or 3,4-dichlorophenyl.















19. The compound of claim 1, wherein the compound is further defined as:












,

,

,

,

,

,

,

,

.














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,





,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,







,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

or a pharmaceutically acceptable salt thereof.

20. A compound of the formula:


,

,

,

, or

;

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising:

(A) a compound according to any one of claims 1-20; and

(B) an excipient;

optionally the pharmaceutical composition is formulated for oral administration, administration via injection such as intraarterial administration, intramuscular administration, intraperitoneal administration, or intravenous administration, or topical administration such as topical administration to the skin or to the eye.

22. The pharmaceutical composition of claim 21, wherein the pharmaceutical composition is formulated for oral administration, administration via injection, or topical administration.

23. The pharmaceutical composition of claim 22, wherein the administration via injection is formulated for intraarterial administration, intramuscular administration, intraperitoneal administration, or intravenous administration.

24. The pharmaceutical composition of claim 22, wherein topical administration is topical administration to the skin or to the eye.

25. A compound or composition according to any one of claims 1-24 for use as a medicament.

26. Use of a compound or composition according to any one of claims 1-24 in the manufacture of a medicament for treating or preventing a disease or disorder selected from an autoimmune disease, an organ rejection, asthma, cancer, a neurological disease, a psychiatric disorder, a neuropsychiatric disorder, chronic pain syndrome, an inflammatory condition, a retinal disorder, or a cardiovascular diseases in a patient in need thereof.